ClearNote Health

ClearNote Health is a privately held biotechnology company dedicated to improving the early detection and monitoring of high-mortality cancers. Headquartered in San Diego, California, the company's mission is to enable individuals at risk for these deadly diseases to live longer, healthier lives by identifying cancer at its earliest, most treatable stages.

The company leverages its proprietary Virtuoso™ epigenomics platform, which integrates advanced biology with artificial intelligence and bioinformatics. This platform analyzes 5-hydroxymethylcytosine (5hmC) biomarkers in cell-free DNA from standard blood draws to detect molecular changes indicative of cancer. ClearNote Health's key products include the non-invasive, blood-based Avantect® Pancreatic Cancer Test and the Avantect® Ovarian Cancer Test, designed for high-risk patient populations. Additionally, it offers epigenomic profiling services to support translational drug development and biopharma partnerships.

In recent news, ClearNote Health secured $52 million in Series D financing in May 2026, bringing its total funding to over $185 million. The company also announced a leadership transition in July 2026, with Kevin Keegan appointed Chief Executive Officer, effective July 31, 2026, succeeding Dave Mullarkey. ClearNote Health has been selected by the National Cancer Institute (NCI) for its Vanguard Study as one of two blood-based technologies for multi-cancer detection and has received UK IVD approvals for its cancer diagnostic tests.